This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Osaka University, Shionogi Company Limited. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 1,044 
2 out of 1,001 
Years Active: 2020-2024
Title: Mitsunobu Matsumoto: Innovator in Cancer Treatment
Introduction
Mitsunobu Matsumoto is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, Matsumoto's work focuses on developing pharmaceutical compositions that target cancer cells effectively.
Latest Patents
Matsumoto's latest patents include a method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells. This invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8. Another significant patent is a method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8. This also offers a pharmaceutical composition for cancer treatment utilizing an antibody against CCR8.
Career Highlights
Throughout his career, Matsumoto has worked with prominent organizations such as Shionogi & Company Limited and Osaka University. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.
Collaborations
Matsumoto has collaborated with esteemed colleagues, including Tetsuya Yoshida and Yujiro Kidani. These partnerships have played a crucial role in enhancing his research and expanding the impact of his inventions.
Conclusion
Mitsunobu Matsumoto is a distinguished inventor whose work in cancer treatment has the potential to change lives. His innovative patents and collaborations reflect his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile